Other Events ·
On September 14, 2026, Phio Pharmaceuticals announced the formal completion of its Phase 1b clinical study for PH-762…
PHIOPhio Pharmaceuticals Corp.
On September 14, 2026, Phio Pharmaceuticals announced the formal completion of its Phase 1b clinical study for PH-762 and submitted a comprehensive briefing package to the FDA. This submission supports the next phase of development in cutaneous squamous cell carcinoma and outlines plans for a Phase 2b neoadjuvant study. Clinical supplies for this upcoming trial are expected to be available in the first quarter of 2027, alongside final activities for nonclinical toxicology studies. Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing siRNA therapeutics using its INTASYL gene silencing technology to treat cancer.